How Trump’s Tariffs on India Could Backfire on the US Healthcare System

Why Washington’s Trade War Might Lead to Drug Shortages & Rising Healthcare Costs

March 14, 2025: 🔹 Key Highlights:

Also Read: Trump Threatens 200% Tariff on European Wines and Champagne Amid Trade War

• Trump’s new tariffs on Indian pharmaceuticals could severely disrupt the US healthcare system by raising drug prices and causing supply shortages.
• India supplies nearly 50% of the US’s generic drugs, contributing $219 billion in healthcare savings in 2022 alone.
• The Indian pharmaceutical industry warns that these tariffs could make exports to the US unviable, leading to manufacturing slowdowns.
• Experts fear the uninsured and low-income Americans will be hit hardest due to price hikes and supply chain disruptions.
• Commerce Minister Piyush Goyal’s visit to the US was aimed at negotiating a trade deal to avoid major economic fallout.

Also Read: Trump Slams India’s ‘Massive’ Tariffs: ‘You Can’t Even Sell Anything There’

---

🔺 Why Indian Pharmaceuticals Matter to the US

Also Read: Jairam Ramesh Alleges Modi-Trump Nexus in Starlink Deal: ‘Who Controls Connectivity in India?’

India plays a critical role in the global pharmaceutical supply chain, with its low-cost, high-quality generic drugs making healthcare affordable in the US.

📌 Fact Check:

• 90% of prescriptions in the US are for generic drugs.
• India is the largest supplier of generics to the US, keeping drug costs 40-60% lower than branded alternatives.
• US pharma imports from India total $8.5 billion annually.

🔻 How Trump’s Tariffs Will Hurt the US

1️⃣ Higher Drug Costs & Shortages:

• Tariffs could make some Indian generics financially unviable, causing shortages of essential medicines.
• US hospitals & pharmacies would struggle to replace lost supplies.

2️⃣ Impact on Uninsured & Low-Income Americans:

• Higher drug prices will disproportionately affect the uninsured and lower-income Americans, who rely on affordable generics.

3️⃣ US Pharma Industry Faces Rising Costs:

• 20% increase in raw material costs since 2017 due to tariffs on China has already raised drug prices.
• Any additional levies on India will further strain the US pharmaceutical industry.

🔺 India’s Response & Trade Talks

• Indian firms like Sun Pharma & Cipla warn they may pull back exports due to cost barriers.
• India may consider zero duty on US drug exports to avoid reciprocal levies.
• Trade negotiations underway:
  • Former US trade official Mark Linscott predicts a partial trade agreement by fall 2025.

---

🔻 The Bigger Picture: A Lose-Lose Situation

✅ The US healthcare system is already struggling with rising costs.
✅ Tariffs could worsen affordability & accessibility of essential medicines.
✅ India risks losing its biggest export market, affecting millions of jobs.

📢 Will a last-minute trade deal save both economies from unnecessary hardship? The coming months will be crucial.

---

📌 Tags:

Trump tariffs India, US healthcare crisis, India pharma exports, drug shortages US, trade war impact, Piyush Goyal US visit, US-India trade deal, rising drug prices, generic drugs supply chain